Literature DB >> 26172088

Methicillin-resistant Staphylococcus aureus in children with atopic dermatitis from 1999 to 2014: A longitudinal study.

Cassandra Chaptini1, Steve Quinn2, Gillian Marshman3.   

Abstract

BACKGROUND/
OBJECTIVES: With the increase in rates of methicillin-resistant Staphylococcus aureus (MRSA) skin infections in the general population, there may be a similar increase of such infections in patients with atopic dermatitis (AD). There are few studies on MRSA prevalence in the AD population, and no previous studies in Australia. This study investigated the prevalence of MRSA and other organisms in the paediatric AD population over the previous 15 years.
METHODS: Skin swab results and other significant data, including patients' characteristics and comorbidities, were collected on patients with AD aged 0-18 years, admitted to a large teaching hospital in South Australia from 1999 to 2014 (N = 298). This longitudinal, retrospective study investigated, using logistic regression, the change of prevalence of MRSA, methicillin-sensitive S. aureus (MSSA) and Streptococcus spp. in AD over the past 15 years.
RESULTS: Compared with 1999-2002, in 2003-2006 patients were approximately threefold more likely (P = 0.350), in 2007-2010 they were approximately 13-fold more likely (P = 0.030) and in 2011-2014 they were approximately 24-fold more likely to test positive for MRSA (P = 0.008), despite low absolute MRSA numbers. There was a positive association between the number of previous hospital admissions per patient and MRSA (OR = 1.16 [1.08-1.25], P = 0.000). In contrast, there was no change in the prevalence of MSSA or Streptococcus spp. over time.
CONCLUSION: The prevalence of MRSA in children with AD is clearly on the rise. This has negative consequences for individuals with AD and is also a major public health problem.
© 2015 The Australasian College of Dermatologists.

Entities:  

Keywords:  Australia; MRSA; Staphylococus aureus; atopic dermatitis; children; eczema; logistic regression; methicillin-resistant Staphylococcus aureus; methicillin-sensitive Staphylococcus aureus

Mesh:

Year:  2015        PMID: 26172088     DOI: 10.1111/ajd.12371

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  8 in total

Review 1.  Efficacy of bleach baths in reducing severity of atopic dermatitis: A systematic review and meta-analysis.

Authors:  Rishi Chopra; Paras P Vakharia; Ryan Sacotte; Jonathan I Silverberg
Journal:  Ann Allergy Asthma Immunol       Date:  2017-11       Impact factor: 6.347

2.  Interventions to reduce Staphylococcus aureus in the management of eczema.

Authors:  Susannah Mc George; Sanja Karanovic; David A Harrison; Anjna Rani; Andrew J Birnie; Fiona J Bath-Hextall; Jane C Ravenscroft; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-10-29

3.  Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis.

Authors:  Allyson L Byrd; Clay Deming; Sara K B Cassidy; Oliver J Harrison; Weng-Ian Ng; Sean Conlan; Yasmine Belkaid; Julia A Segre; Heidi H Kong
Journal:  Sci Transl Med       Date:  2017-07-05       Impact factor: 17.956

4.  Emollient formulations containing antiseptics reduce effectively the level of Staphylococcus aureus on skin.

Authors:  Fabrizio Spada; Tanya M Barnes; Kerryn A Greive
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-09-04

Review 5.  Roles and therapeutic potential of CD1d-Restricted NKT cells in inflammatory skin diseases.

Authors:  Sung Won Lee; Hyun Jung Park; Luc Van Kaer; Seokmann Hong
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

Review 6.  Clinical implications of new mechanistic insights into atopic dermatitis.

Authors:  Donald Y M Leung
Journal:  Curr Opin Pediatr       Date:  2016-08       Impact factor: 2.856

7.  Targeted anti-staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial).

Authors:  Joan Totté; Jill de Wit; Luba Pardo; Frank Schuren; Martijn van Doorn; Suzanne Pasmans
Journal:  Trials       Date:  2017-08-31       Impact factor: 2.279

Review 8.  Applications of Human Skin Microbiota in the Cutaneous Disorders for Ecology-Based Therapy.

Authors:  Hong Zhou; Linlin Shi; Yuanyuan Ren; Xi Tan; Wei Liu; Zhi Liu
Journal:  Front Cell Infect Microbiol       Date:  2020-10-22       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.